Global Search

Hide Filters

Showing 473 results

Press release / Jun 29, 2015

Novartis announces publication in The Lancet showing sustained efficacy with secukinumab over one year in psoriatic arthritis patients

In the FUTURE 2 study, secukinumab demonstrated rapid onset of action, was significantly superior to placebo in improving signs and symptoms of psoriatic arthritis (PsA), with efficacy sustained…
Press release / Oct 10, 2015

Novartis presents new data showing that the majority of patients are able to maintain clear or almost clear skin with Cosentyx across 3 years

Late-breaking data at EADV show that 8 out of 10 of psoriasis patients (83%) achieved 75% skin clearance (PASI 75) with CosentyxTM after three years[1] 6 out of 10 patients (64%) had…
Press release / Feb 16, 2018

Novartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasis

Majority of patients with scalp psoriasis on Cosentyx® (secukinumab) achieved clear skin (PSSI 90) at Weeks 12 and 24 and improved quality of life[1] Scalp psoriasis affects 60 million…
Press release / Jan 21, 2015

Novartis announces FDA approval for first IL-17A antagonist Cosentyx(TM) (secukinumab) for moderate-to-severe plaque psoriasis patients

Offering a new treatment option for patients, Cosentyx is the first approved human monoclonal antibody (mAb) that selectively binds to interleukin IL-17A[1],[2] Phase III data demonstrated…
Press release / Oct 20, 2023

Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer

Late-breaking NATALEE subgroup analysis to be presented at ESMO shows invasive disease-free survival (iDFS) benefit remains consistent in all subgroups, including in patients with stage II tumors,…
Press release / Apr 02, 2019

Novartis first-in-class Cosentyx® approved in China for psoriasis patients

China Health Authority NMPA approved Cosentyx® (secukinumab) for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy Cosentyx is…
Press release / Mar 13, 2015

Novartis to present new late-breaking CosentyxTM data at AAD 2015 showing significant patient benefit in achieving clear skin

Detailed results from the CLEAR study will be revealed showing Cosentyx superiority to Stelara® in clearing skin (PASI 90 and PASI 100)[1] New data from the long-term Phase III program to…
Press release / Jun 06, 2021

Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)

Phase II primary endpoint results for investigational iptacopan in IgAN demonstrated effective and clinically meaningful reduction of proteinuria1 – a key risk predictor in kidney disease…
Press release / Jul 14, 2017

Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis

5 year data from long-term Phase III extension study demonstrate sustained efficacy and safety of Cosentyx in patients with moderate-to-severe plaque psoriasis[1] Data planned to be…
Press release / Mar 06, 2018

Novartis' Xolair® recommended in new global chronic urticaria guideline

Xolair® (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU)[1], is the only therapy recommended by the guideline for patients unresponsive to…